This editorial summarizes the current evidence and the authors' perspective regarding the role of mTOR inhibitors and cancer in kidney transplant recipients. See article by Campbell et al on page 1146.
|Number of pages||2|
|Journal||American Journal of Transplantation|
|Publication status||Published - May 2012|
- kidney transplantation
- Mammalian target of rapamycin (mTOR) inhibitors